Released Apr 30, 2021, before the open
10-Q filed Apr 30, 2021, 30 days after period end · 0001564590-21-022230
Q1 2021 · 10-Q
Revenue$105.59M$105.59M +0.7% vs Q1 2020−10.2% vs Q4 2020
Net Income-$5.82M-$5.82M N/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.30-$0.30 N/M vs Q1 2020no prior Q4 2020 on file
Gross Profit$79,679,000−2.1%
Operating Income-$2,916,000N/M
Operating Cash Flow$2,441,000−80.4%
Free Cash Flowderived-$1,924,000N/M
Margins · derived
Gross margin75.5%−2.2 pt vs Q1 2020
Operating margin-2.8%−9.3 pt vs Q1 2020
Net margin-5.5%−30.0 pt vs Q1 2020
What the release said
The release
Same quarter
| Metric | Q1 2021 | Q1 2020 | Q1 2019 | Q1 2018 |
|---|---|---|---|---|
| Revenue | $105.59M | $104.82M | $109.11M | $108.71M |
| Net Income | -$5.82M | $25.67M | $897.00K | $5.23M |
| EPS Diluted | -$0.30 | $1.32 | $0.05 | $0.27 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR